Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of filgotinib in rheumatoid arthritis
NL-OMON47791Phase 3Withdrawn
- Sponsor
- Gilead Sciences
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of filgotinib in rheumatoid arthritis (RA) (2 arms), sponsored by Gilead Sciences. Primary endpoints: Long-term safety and ACR-N response. Planned start Sep 2017; status: withdrawn.
02
Drugs
filgotinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON47791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47791.